News & Events

M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitors

M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitors

Olomorasib Earns FDA Breakthrough Therapy in KRAS G12C+ Pancreatic Cancer

Olomorasib Earns FDA Breakthrough Therapy in KRAS G12C+ Pancreatic Cancer

Silexion reports new preclinical immune data for SIL204 in KRAS cancers

Silexion reports new preclinical immune data for SIL204 in KRAS cancers

Serum cytokine profiles in a real-world cohort of KRAS-Mutant NSCLC and its therapeutic implications for subtype-specific immunotherapy

Serum cytokine profiles in a real-world cohort of KRAS-Mutant NSCLC and its therapeutic implications for subtype-specific immunotherapy

Radio-sensitization of mutated KRAS G12C non-small cell lung cancer with KRAS G12C tyrosine kinase inhibitor and carbon ions irradiation

Radio-sensitization of mutated KRAS G12C non-small cell lung cancer with KRAS G12C tyrosine kinase inhibitor and carbon ions irradiation

Real-world treatment pattern and clinical outcomes in Chinese NSCLC patients with KRAS G12C mutation

Real-world treatment pattern and clinical outcomes in Chinese NSCLC patients with KRAS G12C mutation

InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRAS G12C Mutation

InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRAS G12C Mutation

Getting to the Bone of the Matter: Bone-Modifying Agents

Getting to the Bone of the Matter: Bone-Modifying Agents

LUNGevity offers a variety of virtual support groups called ‘meetups’ where survivors and caregivers impacted by lung cancer connect with others who understand the patient experience.  Once a month, we invite an expert to share information on a topic related to life with lung cancer, engage with attendees, and answer questions in real time. Visit the LUNGevity Calendar to see upcoming events like this one.In June, we welcomed Duc Huynh, PharmD, BCOP, MD Anderson Cancer Center, to talk…

Camila Bermúdez García: Turning Experience into Advocacy

Camila Bermúdez García: Turning Experience into Advocacy

Before lung cancer entered her life, 24-year-old Camila Bermudez Garcia was focused on building her future. Growing up as the oldest of three in Ponce, Puerto Rico, she was surrounded by a close-knit family and immersed herself in music, science, and community service. She played the viola in an orchestra, sang and played piano in church, and was preparing to apply to medical school after earning a Master’s in Medical Sciences.  Her interest in healthcare began years earlier after her…

Benjamin P. Levy, MD, on KRAS G12C–Mutated NSCLC: Current Treatment Landscape

Benjamin P. Levy, MD, on KRAS G12C–Mutated NSCLC: Current Treatment Landscape

Benjamin P. Levy, MD, on Emerging Options for KRAS G12C–Mutated NSCLC: First-Line and Combination Therapies

Benjamin P. Levy, MD, on Emerging Options for KRAS G12C–Mutated NSCLC: First-Line and Combination Therapies

Harpreet Singh: A New Benchmark for KRAS G12C Targeted Therapy in NSCLC

Harpreet Singh: A New Benchmark for KRAS G12C Targeted Therapy in NSCLC

Podcast: Clinical Trials - Who's Eligible, and How to Find One

Podcast: Clinical Trials - Who's Eligible, and How to Find One

How do clinical trials work? What actually happens when you enroll in one? And how do you find a trial that's right for you?In this episode, small cell lung cancer survivor Wendy Brooks and thoracic oncologist Arthi Sridhar, MD, UT Southwestern Medical Center, join hosts Ann Steagall and Dr. Misty Shields to break down the intricacies of clinical trials—phases, safeguards in place, and what it's like to be a part of one.Listen as Wendy shares her own experience moving through multiple trials…

Top Lung Cancer Research Highlights from ASCO 2026

Top Lung Cancer Research Highlights from ASCO 2026

Each year, the American Society of Clinical Oncology (ASCO) Annual Meeting brings together the world’s largest gathering of the oncology community. Approximately 40,000 researchers, physicians, nurses, advocates, biotech and pharmaceutical professionals, and others, meet annually to discuss research that shapes how cancer is diagnosed, treated, and managed.The 2026 meeting took place May 29 - June 2 in Chicago and included important advances in lung cancer treatment. We saw awe-inspiring long-…

Podcast: What are Biomarkers and Why Should You Get Tested?

Podcast: What are Biomarkers and Why Should You Get Tested?

 What are biomarkers, why do they matter, and what should every person living with lung cancer know about getting tested? Dr. Ross Camidge, a world-renowned thoracic oncologist and lung cancer researcher at the University of Colorado, joins Ann Steagall and Dr. Misty Shields to explain the ins and outs of biomarkers. Dr. Camidge helped pioneer biomarker testing as a standard of care, but he also brings the patient perspective as well - he was diagnosed with EGFR-mutant non-small cell lung…

Neuropathy and Lung Cancer: What Patients Need to Know

Neuropathy and Lung Cancer: What Patients Need to Know

LUNGevity offers a variety of virtual support groups called ‘meetups’ where survivors and caregivers impacted by lung cancer connect with others who understand the patient experience.  Once a month, we invite an expert to share information on a topic related to life with lung cancer, engage with attendees, and answer questions in real time. In May, we welcomed Aileen Anglin, ACNP-BC, AOCNP, from MD Anderson Cancer Center, to talk about peripheral neuropathy. Peripheral neuropathy…

Precision, Partnership, Purpose: Lung Cancer Highlights from AACR 2026

Precision, Partnership, Purpose: Lung Cancer Highlights from AACR 2026

The American Association for Cancer Research (AACR) Annual Meeting brought together thousands of cancer researchers, clinicians, advocates, and patients in San Diego from April 17–22. This year's theme—“Precision, Partnership, Purpose: Advancing Cancer Science to Save Lives Globally”—set a powerful tone for a meeting that showcased advances across the lung cancer landscape.  One message was loud and clear. Science is accelerating, and we are reimagining how healthcare is delivered. From…

Podcast: Making the Most of Your Healthcare Visits

Podcast: Making the Most of Your Healthcare Visits

How do you make the most of your visits with your healthcare team? In this episode, lung cancer survivor Bill Morris shares his experience with lung cancer and how he approaches his healthcare visits now. Oncology nurse practitioner Rasheda Persinger shares her insights after 20 years of working with patients. Hosts Ann and Dr. Shields discuss with Bill and Rasheda what they wish every patient knew, from writing down questions before an appointment to asking about biomarker testing to why…

Watch HOPE Summit 2026 Videos

Watch HOPE Summit 2026 Videos

HOPE Summit 2026 was filled with old friends reuniting, new friends being made, and of course, plenty of inspirational and informative sessions designed to help people live well with lung cancer.For the second year in a row, select sessions were recorded so those who could not attend are still able to access the valuable information shared.HOPE Summit 2026 Recorded Sessions Keynote: Wagons Roll with Dr. Ross Camidge  Back in the Saddle: Reclaiming Strength and Living Well …

Clinical Trial Access Isn’t Expanding. It’s Concentrating.

Clinical Trial Access Isn’t Expanding. It’s Concentrating.

Clinical trials show us whether a new treatment is safe and effective. They are also an important way for patients to access cutting-edge care. For trials to truly serve the lung cancer community, the people who enroll in the trials need to represent the populations who are diagnosed in everyday life.Recognizing these needs, federal agencies like the United States Food and Drug Administration (FDA) have been encouraging clinical trials to offer more locations across the US.The PlanThe intention…

Podcast: Why Community Matters in Lung Cancer Care

Podcast: Why Community Matters in Lung Cancer Care

Why does finding community matter in lung cancer care? In this episode, lung cancer survivor and advocate Jill Feldman shares her experience, from losing multiple family members to lung cancer to her own diagnosis, as well as her work building patient communities around the world. She discusses how connecting with others has shaped her journey and why community is important for support, information, and advocacy.Hosts Ann Steagall, RN, BSN, and Misty Shields, MD, PhD, explore with Jill how…

Podcast: Lung Cancer Diagnosis—What Happens Next

Podcast: Lung Cancer Diagnosis—What Happens Next

What happens after a lung cancer diagnosis? In this first episode of LUNGevity’s Lung Cancer Voices of Hope podcast, lung cancer survivor Lisa Bistline shares her experience, from initial scans and biopsies through multiple treatments, and the moment a later biopsy revealed a biomarker that led to a targeted therapy.Hosts Ann Steagall and Misty Shields, MD, PhD, then speak with Anne Chiang, MD, PhD, thoracic oncologist at Yale University, about what patients can expect at their first visit,…

Scalp Care, Shaving, and Head Coverings: Comfort Through Hair Loss

Scalp Care, Shaving, and Head Coverings: Comfort Through Hair Loss

This video is a recording from a LUNGevity virtual meetup. Each month, we host multiple virtual meetups for those impacted by lung cancer to meet and connect with others who understand them and what they’re going through.Periodically, we invite an expert to speak on a topic at the beginning of a meetup, with the second half dedicated to questions and conversation. Visit the online calendar to see our virtual meetups and other upcoming events.For this meetup, we welcomed Jenna Doyle Ruhl and…

Meet The “Mini-Organs” of Lung Cancer Research

Meet The “Mini-Organs” of Lung Cancer Research

Though many of us would like to deny it, our neighbors affect us. Their loud music disturbs our sleep. The scent of their dinner wafts through an open window. The sight of their new puppy brings a smile. We interact with our environment every moment of the day. And so do lung cancer cells.  A Brief HistoryTraditionally, we have studied tumor cells in isolation. We often study single cells in a petri dish, or under a microscope, to understand how they work. This has been very important and…

Three Moments That Defined the 2026 Targeted Therapies of Lung Cancer Conference

Three Moments That Defined the 2026 Targeted Therapies of Lung Cancer Conference

The 2026 Targeted Therapies of Lung Cancer Meeting brought together leading clinicians, researchers, and patient advocates to discuss the latest advances shaping the future of lung cancer care. Hosted by the International Association for the Study of Lung Cancer, this annual gathering was held in Huntington Beach, California from Feb. 18-21, 2026. It has become known as one of the key meetings for participants to discuss the latest breakthroughs and challenges in lung cancer.This year’s meeting…

Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer

Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer

Every January, the American Cancer Society releases a Cancer Facts & Figures report. It provides a clear view of where we stand in addressing cancer. The 2026 report brings both encouraging news and a sobering reminder that our work is far from over.The Big Picture Shows Real ProgressLet’s start with the good news. We have made significant strides in cancer care over the past three decades. Since 1991, the cancer death rate has dropped by 34%. This translates to approximately 4.8 million…

Artificial Intelligence in Lung Cancer: Hope vs. Hype

Artificial Intelligence in Lung Cancer: Hope vs. Hype

Artificial intelligence (AI) is rapidly reshaping the future of cancer care, but such dramatic innovation also brings important questions.AI has evolved from early consumer tools (like autocorrect on phones, customer service chatbots, and personalized shopping recommendations) to advanced systems with the potential to revolutionize biomedical discovery and patient care. While there is tremendous excitement around AI, there is also a critical need to use it responsibly.Researchers are actively…

Why Immunotherapy Isn’t Perfect & How Scientists Are Working to Fix It

Why Immunotherapy Isn’t Perfect & How Scientists Are Working to Fix It

The human immune system is an intricate web of checks and balances that usually excels at detecting and destroying foreign invaders, such as bacteria and viruses, while protecting healthy tissue. But sometimes, the checks and balances get confused and stop the immune system from doing what’s right—such as killing tumor cells.  Tumor cells are good at confusing the immune system because they originate from our healthy cells. They can often avoid detection by immune cells. Through several…

New Horizons in Immunotherapy: Lung Cancer Highlights from the 2025 SITC Meeting

New Horizons in Immunotherapy: Lung Cancer Highlights from the 2025 SITC Meeting

The Society for Immunotherapy of Cancer (SITC) celebrated their 40th anniversary at their annual meeting in National Harbor, Maryland from November 5-9, 2025. The meeting focused on multidisciplinary research aiming to leverage the immune system to improve outcomes for cancer patients, including  several exciting areas of growth in lung cancer-directed immunotherapy.Tumor Imaging is Growing More Powerful  Advanced imaging techniques are poised to change how we understand and treat…

The Future of Lung Cancer Starts Here

The Future of Lung Cancer Starts Here

For more than two decades, LUNGevity Foundation has been a leader in advancing lung cancer research. Since 2002, we have invested  $55+ million in more than 200 research projects, helping to build a robust pipeline of discoveries in early detection, treatment innovation, and health equity.Once again, LUNGevity is ready to open our annual grant cycle in 2026 with five research programs designed to address the most pressing challenges in lung cancer care. In addition, these grants ensure the…